GLYXAMBI Solution for Injection
Empagliflozin, Linagliptin
25 mg + 5 mg
Boehringer Ingelheim Pharma GmbH & Co. KG
| Pack size | 30's Pack |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 7.54 AED |
Indications
GLYXAMBI Solution for Injection is used for:
Empagliflozin
Empagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes.
Linagliptin
Linagliptin is indicated for the treatment of type II diabetes in addition to diet and exercise[FDA Label]. It should not be used to treat type I diabetes or in diabetic ketoacidosis[FDA Label].
Empagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes.
Linagliptin
Linagliptin is indicated for the treatment of type II diabetes in addition to diet and exercise[FDA Label]. It should not be used to treat type I diabetes or in diabetic ketoacidosis[FDA Label].
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Empagliflozin, Linagliptin :
Mechanism of Action
Empagliflozin
Empagliflozin is a sodium glucose co-transporter-2 (SGLT-2) inhibitor. SGLT2 co-transporters are responsible for reabsorption of glucose from the glomerular filtrate in the kidney. The glucuretic effect resulting from SGLT2 inhibition reduces renal absorption and lowers the renal threshold for glucose, resulting in increased glucose excretion. Additionally, it contributes to reduced hyperglycaemia, assists weight loss, and reduces blood pressure.
Linagliptin
Linagliptin is a competitive, reversible DPP-4 inhibitor. Inhibition of this enzyme slows the breakdown of GLP-1 and glucose-dependant insulinotropic polypeptide (GIP)[FDA Label][A37050]. GLP-1 and GIP stimulate the release of insulin from beta cells in the pancreas while inhibiting release of glucagon from pancreatic beta cells[FDA Label]. These effects together reduce the breakdown of glycogen in the liver and increase insulin release in response to glucose[FDA Label][A37050].
Empagliflozin is a sodium glucose co-transporter-2 (SGLT-2) inhibitor. SGLT2 co-transporters are responsible for reabsorption of glucose from the glomerular filtrate in the kidney. The glucuretic effect resulting from SGLT2 inhibition reduces renal absorption and lowers the renal threshold for glucose, resulting in increased glucose excretion. Additionally, it contributes to reduced hyperglycaemia, assists weight loss, and reduces blood pressure.
Linagliptin
Linagliptin is a competitive, reversible DPP-4 inhibitor. Inhibition of this enzyme slows the breakdown of GLP-1 and glucose-dependant insulinotropic polypeptide (GIP)[FDA Label][A37050]. GLP-1 and GIP stimulate the release of insulin from beta cells in the pancreas while inhibiting release of glucagon from pancreatic beta cells[FDA Label]. These effects together reduce the breakdown of glycogen in the liver and increase insulin release in response to glucose[FDA Label][A37050].
Note
GLYXAMBI 25 mg + 5 mg Solution for Injection manufactured by Boehringer Ingelheim Pharma GmbH & Co. KG. Its generic name is Empagliflozin, Linagliptin. GLYXAMBI is availble in Saudi Arabia.
Farmaco SA drug index information on GLYXAMBI Solution for Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.